Search
Descriptor English: Atrasentan
Descriptor Spanish: Atrasentán
Descriptor atrasentán
Entry term(s) (11C)ABT-627
A 127722
A 127722.5
A 147627
A-127722
A-127722.5
A-147627
A127722
A127722.5
A147627
ABT 627
ABT-627
ABT627
Xinlay
clorhidrato de atrasentán
hidrocloruro de atrasentán
ácido 2-(4-metoxifenil)-4-(1,3-benzodioxol-5-il)-1-(((dibutilamino)carbonil)metil)pirrolidin-3-carboxílico
Scope note: Derivado pirrolidínico y benzodioxólico que actúa como antagonista del RECEPTOR DE ENDOTELINA A. Tiene potencial terapéutico como antineoplásico y para el tratamiento de las NEFROPATÍAS DIABÉTICAS.
Descriptor Portuguese: Atrasentana
Descriptor French: Atrasentan
Entry term(s): (11C)ABT-627
2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid
A 127722
A 127722.5
A 147627
A-127722
A-127722.5
A-147627
A127722
A127722.5
A147627
ABT 627
ABT-627
ABT627
Atrasentan Hydrochloride
Xinlay
Tree number(s): D03.383.246.118.300
D03.383.773.079
D03.633.100.115.300
RDF Unique Identifier: https://id.nlm.nih.gov/mesh/D000077868
Scope note: A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.
Allowable Qualifiers: AA analogs & derivatives
AD administration & dosage
AE adverse effects
AG agonists
AI antagonists & inhibitors
AN analysis
BL blood
CF cerebrospinal fluid
CH chemistry
CL classification
CS chemical synthesis
EC economics
HI history
IM immunology
IP isolation & purification
ME metabolism
PD pharmacology
PK pharmacokinetics
PO poisoning
RE radiation effects
SD supply & distribution
ST standards
TO toxicity
TU therapeutic use
UR urine
Pharm Action: Antineoplastic Agents
Endothelin A Receptor Antagonists
Registry Number: V6D7VK2215
CAS Type 1 Name: 3-Pyrrolidinecarboxylic acid, 4-(1,3-benzodioxol-5-yl)-1-(2-(dibutylamino)-2-oxoethyl)-2-(4-methoxyphenyl)-, (2R,3R,4S)-
Public MeSH Note: 2019; ATRASENTAN was indexed under PYRROLIDINES 1996-2018
History Note: 2019 (1996)
DeCS ID: 57771
Unique ID: D000077868
Documents indexed in the Virtual Health Library (VHL): Click here to access the VHL documents
Date Established: 2019/01/01
Date of Entry: 2018/07/09
Revision Date: 2018/05/21
Atrasentan - Preferred
Concept UI M0393223
Scope note A pyrrolidine and benzodioxole derivative that acts a RECEPTOR, ENDOTHELIN A antagonist. It has therapeutic potential as an antineoplastic agent and for the treatment of DIABETIC NEPHROPATHIES.
Preferred term Atrasentan
A 127722 - Narrower
Concept UI M0259089
Preferred term A 127722
Entry term(s) A 127722.5
A-127722
A-127722.5
A127722
A127722.5
Atrasentan Hydrochloride - Narrower
Concept UI M000642029
Preferred term Atrasentan Hydrochloride
A 147627 - Narrower
Concept UI M0259083
Preferred term A 147627
Entry term(s) A-147627
A147627
ABT 627 - Narrower
Concept UI M0259087
Preferred term ABT 627
Entry term(s) ABT-627
ABT627
2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid - Broader
Concept UI M000642028
Preferred term 2-(4-Methoxyphenyl)-4-(1,3-benzodioxol-5-yl)-1-(((dibutylamino)carbonyl)methyl)pyrrolidine-3-carboxylic acid
(11C)ABT-627 - Narrower
Concept UI M0498965
Preferred term (11C)ABT-627
Xinlay - Narrower
Concept UI M0484205
Preferred term Xinlay



We want your feedback on the new DeCS / MeSH website

We invite you to complete a survey that will take no more than 3 minutes.

Go to survey